Keywords
Treatment
Chronotherapy
Steroid Synthesis Inhibitors
Antiglucocorticoid
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the efficacy and safety of new therapeutic approaches in the treatment of Cushing's syndrome. Methods: An Integrative Review was carried out using the PubMed data platform in order to find relevant sources for this purpose. The search was carried out using the following search strategy: ("Cushing Syndrome"[MeSH]) AND ((Treatment) OR (Chronotherapy) OR (Steroid Synthesis Inhibitors) OR (Antiglucocorticoid)). Initially, there were 600 articles and, by applying the inclusion and exclusion criteria, 17 articles were selected for analysis in this study. Results: Studies indicate that Osilodrostat is safe and effective in controlling hypercortisolism, but it has various adverse effects. Ketoconazole is effective and safe for active disease after transsphenoidal surgery. Pasireotide improves quality of life, clinical signs, and has various side effects. 9-cis retinoic acid may be beneficial with additional adrenal effects, and S-707106 improves insulin sensitivity and reduces obesity. Levoketoconazole has shown effectiveness in clinical presentation, tolerability, and safety. Relacorilant has demonstrated clinical benefits, and Metyrapone has good solubility and safety. In cases of recurrence, some points should be considered when using external radiotherapy as adjunctive therapy. Final Considerations: The new therapeutic approaches studied can be considered safe and effective for Cushing's syndrome.
References
BRAUN LT e REINCKE M. What is the role of medical therapy in adrenal-dependent Cushing's syndrome?. Best Pract Res Clin Endocrinol Metab, 2020; 34(3): 101376.
CECCATO F, et al. Metyrapone treatment in Cushing's syndrome: a real-life study. Endocrine, 2018; 62(3): 701-711.
DETOMAS M, et al. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study. Frontiers in Endocrinology, 2022; 13: e903545.
DUGGAN S. Osilodrostat: first approval. Drugs, 2020; 80(5): 495-500.
DZIALACH L, et al. Cushing’s syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia. Hormones, 2022; 21(4): 735-742.
EFSTATHIADOU ZA, et al. Complete and sustained remission of hypercortisolism with pasireotide treatment of an adrenocorticotropic hormone (ACTH)-secreting thoracic neuroendocrine tumor: an n-of-1 trial. Endocrine Journal, 2023; 70(2): 229-232.
FLESERIU M, BILLER BMK. Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples. Pituitary, 2022; 25(6): 795-809.
FLESERIU M, et al. "Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study." Clinical Endocrinology, 2019; 91(6): 776-785.
FLESERIU M, et al. Efficacy and safety of levoketoconazole in the treatment ofendogenous Cushing’s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. The Lancet Diabetes & Endocrinology, 2019; 7(11): 855-865.
FLESERIU M, et al. Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. European journal of endocrinology, 2022; 187(6): 859-871.
GHEORGHIU ML, Updates in the outcomes of radiation therapy for Cushing's disease. Best practice & research. Clinical endocrinology & metabolism, 2021; 35(2): 101514.
GIRALDI FP, et al. Dual effects of 9-cis retinoic acid on ACTH-dependent hyperplastic adrenal tissues. Sci Rep, 2021; 11(1): 14315.
HINOJOSA-AMAYA JM, et al. Medical management of Cushing’s syndrome: current and emerging treatments. Drugs, 2019; 79: 935-956.
LACROIX A, et al. Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study. J Endocrinol Invest, 2020; 43(11): 1613-1622.
ODA S, et al. An Open-label Phase I/IIa Clinical Trial of 11β- HSD1 Inhibitor for Cushing’s Syndrome and Autonomous Cortisol Secretion. J Clin Endócrino Metab, 2021; 106(10): e3865-e3880.
PEROSEVIC M, TRITOS NA. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature. Drug Design, Development and Therapy, 2023; 17: 1303-1312.
PIVONELLO R, et al. Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Front Endocrinol (Lausanne), 2021; 12: 662865.
PIVONELLO R, et. al. Cushing's disease: adrenal steroidogenesis inhibitors. Pituitary, 2022; 25(5): 726-732.
VIECCELI C, et al. Evaluation of ketoconazole as a treatment for Cushing's disease in a retrospective cohort. Frontiers in Endocrinology, 2022; 13: 1-13.
VIECCELI C, et al. Ketoconazole as second-line treatment for Cushing’s disease after transsphenoidal surgery: systematic review and meta-analysis. Frontiers in Endocrinology, 2023; 14: 1-8.